MUNI
MED

NSAIDs, Antipyretics, Antigout drugs

Department of Pharmacology MU

- **Analgesics-antipyretics (A-A)** drugs against fever and pain

- **Nonsteroidal antiinflammatory drugs (NSAIDs)** - against inflammation, fever and pain

---

A-A and NSAIDs overlap partially

- **Antigout drugs** – gout therapy

MUNI MED

Mechanism of action

- all of them have similar mechanism of action– inhibition of eicosanoids synthesis (with higher or lower selectivity and strength)

- NSAIDs differ in the strength of COX1/COX2 inhibition and the incidence of typical AE (ulcer disease, bleeding)

MUNI
MED

Cyclooxygenases

- **COX-1 – constitutive** – prostanoids involved in physiological processes (gastroprotective effects, platelet activities)
- **COX-2 – inducible** – activity enhanced by proinflammatory factors (IL-1, IL-2, TNF-α, oncogenes,..)
  - prostanoids → inflammation, fever, pain
- **COX-3** ? – central mechanism of analgesic and antipyretic effect (localization: heart + CNS)

MUNI MED

Classification by COX1/COX2 inhibition

1. Nonspecific inhibitors
   - ASA, ibuprofen, diclofenac, …

2. Preferential inhibitors of COX-2
   - meloxicam, nimesulid

3. Specific inhibitors of COX-2
   - coxibs

MUNI MED

Classification

1. Salicylic acid derivatives
2. Aniline derivatives
3. Propionic acid derivatives
4. Pyrazolones
5. Acetic acid derivatives
6. Oxicams
7. Coxibs
8. Other

MUNI MED

1. Salicylates

Effects:

- analgesic
- antiinflammatory
- antipyretic
- antirheumatic
- antiaggregation → inhibition of platelet function

MUNI
MED

Salicylic acid derivatives – drugs

NSAIDs:

- ASA (acetylsalicylic acid)
- sodium salicylate
- cholinsalicylate

Therapy of inflammatory bowel desease:

- sulfasalazine

  → sulfapyridine + 5-aminosalicylic acid

- mesalazine

MUNI MED

Acetylsalicylic acid

- efficiency standard of AA and NSAIDs
- selective inhibitor of COX1 (100-200 : 1)
- irreversible acetylation of COX-1 active centre
- pharmacokinetics:
  - weak acid, complete and rapid absorption in stomach and proximal part of intestine
  - **salicylic acid (SA)** is product of metabolisation
  - $T_{1/2}$ ASA 15-20 min, $T_{1/2}$ SA 30 hrs depending to dose
  - 80-95% binding to plasma proteins, elimination and exkretion via kidneys
  - higher doses – risk of cumulation in a body

MUNI MED

Usual dosages

• antipyretic	**500 mg**
• analgesic	**500 mg (4 - 6 hrs)**
• anti-phlogistic, -rheumatic, -uratic	**3,6 – 4 g/day**
• antiaggregative	**30 –100 mg**
• total daily dose	**4 g/day**

MUNI
MED

ASA – adverse effects

- **salicylism (↑d.)** – hearing impairment, tinnitus, deafness, vertigo
- **allergy** - itching, rash, anaphylaxis,…
- **aspirin-induced asthma** - ↑LT
- **GIT** - nausea, dyspepsia, bleeding, ulcer disease
- **„analgetic“ nephropathy** – reversible decrease of glomerular filtration
- **increased bleeding**

CAVE

- pregnancy- differs in trimesters
- children- Rey‘s syndrome
- elders- more sensitive to AE

MUNI MED

ASA interactions

- **anticoagulants**
- **NSAIDs** and other analgesics (except of opioids)
- **other**
  - valproate, sulfonylureas – competition on plasma proteins – increase of efficacy
  - SSRI – potentiate ASA antiaggregative effect (citalopram, fluoxetine)
  - glucocorticoids decrease ASA plasma levels, but increase the risk of GIT bleeding and ulceration

MUNI MED

ASA - contraindications

- hemophilia and other diseases influencing blood coagulation
- administration prior to surgery
- gastroduodenal ulcers, gastritis
- **children to 12 years**
  - **Rey‘s syndrome** (hyperpyrexia, acidosis, seizures, vomiting, psichiatric disorders, hepatopathy)
- pregnancy (only temporary)
- asthma, allergy, nasal polyps

MUNI MED

2. Aniline derivatives

Paracetamol (=acetaminophen)

- analgesic, antipyretic, **is not antiinflammatory active**
- does not influence blood coagulation or uric acid levels
- mechanism of action is unclear:
  - central mechanism due to COX-3 inhibition
  - indirect effect on 5-HT_3 spinal receptors
  - elevates PGG_2 to PGH_2conversion in peripheral tissues
  - influencing the endocannabinoid and vanillin system and Ca^{2+} channels

MUNI MED

Usual doses

- comparable effect to ASA, but better tolerance
- **drug of choice to ↓ fever and pain in children younger than 12 years**
- pain in adults
  - 300 to 500 mg every 3-4 hrs
  - 650 mg every 4 to 6 hrs
  - 1000 mg every 6 hrs
- total daily dose up to **4 g**

MUNI MED

Pharmacokinetics:

- p.o. good absorbtion, maximum in 30-60 min, low plasma protein binding, hepatic metabolism
- production of hepatotoxic mtb. – binding to gluthathione
- overdose (10 – 15 g) → antidote **N-acetylcysteine**

AE, CI:

- allergy
- hepatotoxicity after ↑ doses
- comorbidities:
  - alcohol addiction
  - nephropathy
  - hepatopathy

MUNI MED

3. Pyrazolones

Propyphenazone

- in combinations (with paracetamole and caffein)
- **AE:** GIT intolerations, rash, bronchospasm, hematopoetic disorders

Metamizole

- analgetic, antipyretic + spasmolytics effect
- combined with spasmolytics (pitofenone, fenpiverine)
- **AE:** rare but serious - the most serious are agranulocytosis and pancytopenia

MUNI MED

4. Propionic acid derivatives

Ibuprofen

- good analgesic and antiinflammatory effect
- used often for acute pain therapy
- low AE incidence, well tolerated NSAID, indicated for children

Ketoprofen

- phototoxicity

Dexketoprofen

MUNI
MED

4. Propionic acid derivatives

Naproxen

- longer $T_{1/2}$ (12-15 hrs)
- low gastro- and cardiovascular toxicity compared to other NSAIDs

Tiaprofenic acid

- good penetration to synovial fluid → joints diseases

Flurbiprofen

MUNI MED

5. Acetic acid derivatives

Diclophenac

- antiinflammatory, analgesic, weak antipyretic ef.
- bioavailability 30-70%
- short biological halftime → retarded DDF
- more AE than ASA, less than indomethacin
  - mild: cephalgia, insomnia, GIT disorders, photosensitivity
  - significant risk of cardiovascular AE

Aceclofenac

MUNI MED

5. Acetic acid derivatives

Indomethacin

- very strong nonselective COX inhibitor
- toxic → short-time treatment of acute states
- urikosuric effects→ used in gout attacks
- AE in 30 % of pacients
  - GIT, cephalgia, depression, confusion, hallucinations, hematoxicity, cartilages destruction

MUNI MED

6. Oxicams

- high plasma protein binding (interactions!)
- long biological halftime (once daily dosing)
- different COX affinity

Meloxicam

- COX-2 more selective
- lower AE incidence

Locnoxicam

- nonselective COX inhibitor
- low occurence of GIT adverse effect

Piroxicam

- nonselective COX inhibitor, high toxicity

MUNI MED

7. Coxibs

- 100 x more selective to COX-2 (**specific** COX-2 inhibitors)
  - lower AE in GIT
  - do not influence thrombocyte aggregation or renal perfusion
- good analgesic effect, not suitable for treatment of acute or transient pain → effect is progressing slowly
- prescription and indication restrictions
- **I:** osteoarthritis, rheumatoid arthritis, ankylosing spondylitis
- **AE:** increase of thrombembolisms (myocardial infarction, strokes) after chronic use

MUNI MED

7. Coxibs

Celecoxib

Parecoxib – only inj.

Etoricoxib

Pharmacokinetics:

- after p.o. administration good absorption from GIT, but not too fast, max levels reach in 2-4 hours
- fat diet slows down absorption

MUNI MED

8. Other

Nimesulide

- preferential inhibitor of COX-2
- inhibits enzymes destroys cartilage (elastases, collagenases), due to occurrence of AE, indication of treatment of painful osteoarthritis has been taken
- is not the first choice medicine in any of indications
- **PK:** lipophilic, short elimination half-life (1,5-5 hrs), analgesia up to 12 hrs
- **AE:** hepatotoxicity (max duration of therapy 15 days)

MUNI
MED

Adverse effects

- because of COX-1 inhibition:
  - GIT - ↓ cytoprotective PGE_2, PGI_2
    ⇒ ***erosions, ulcerations***
  - thrombocytes - ↓ TXA_2: inhibition of thrombocytes aggregation
    ⇒ ***increased bleeding***
  - PGE_2, PGI_2 regulation of renal functions
    ⇒ ***renal failure***
  - ↑ LT production induces in predisposed people bronchoconstriction
    ⇒ ***asthma attack***
  - uterus - ↓ PGE/F: inhibition of constriction
    ⇒ ***prolongation and complications during delivery***

- coxibs:
  - thromboembolic cardiovascular and cerebrovascular complic

MUNI MED

Prevention of AE

- dose reduction or DDF change
- combination with protective drugs
  - **proton pump inhibitors** (lansoprazole, omeprazole)
  - **prostaglandine analogues** (misoprostol)
  - **H_2 antihistamines** (ranitidine, famotidine)

- think about preferential or specific COX-2 inhibitors

MUNI
MED

NSAIDs for local aplication

- ketoprofen, ibuprofen, naproxen, indomethacin, diclophenac, nimesulide, piroxicam
- flurbiprofen (lozenges), choline salicylate (oral gel)
- **DDF:** creams, gels, solutions (sprays), patches, lozenges
- **AE:** hypersensitivity reaction, phototoxic reaction

MUNI MED

Treatment of gout

MUNI
MED

Drugs

1. **Acute gout attack**
   - strong anti-inflammatory action
   - pain-killers
   - inhibition of leucocyte migration to the joint
2. **Hyperuricemia therapy / prevention of gout attack**
   - increase of uric acid excretion
   - block of synthesis

   + diet

MUNI MED

Treatment of acute gout attack

- **NSAIDs**
  - higher doses (i.m., p.o., p.r.)
  - some have preferably uricosuric effect
  - **indometacine, diclofenac, piroxicam**

- **colchicine**
  - alcaloid obtained from *Colchicum autumnale*
  - p.o. every 2-4 hrs
  - mitotic poison, inhibits phagocytosis and leukocyte migration
  - **AE:** severe diarrhea – rehydratation!

- **glucocorticoids**
  - local adm. (i.a.) – **triamcinolone**
  - systemic (p.o., i.m., i.v.) – **prednison**, **methylprednisolon**

- **canakinumab**
  - IL-1 inhibitor, human monoclonal antibody
  - patients who do not tolerate NSAIDs and GC
  - s.c. aplication

MUNI MED

Chronic treatment of gout

1. Uricosurics

- inhibit reabsorption of uric acid in primary tubulus

Lesinurad

- only in combination with xantin oxidase inhibitors

Probenecide

- sometimes used with antibiotics or antivirotics to make them stay longer in the body
- Not registered in Czech Rep.

MUNI MED

2. Antiuratics

- inhibit syntesis of urine acid by inhibition **xantin oxidase (XO)**

Allopurinol

- isomer of hypoxanthin, competitive inhibition of xanthin oxidase
- inhibits *de novo* syntesis of purines
- not combine with cytostatics of purine structure (azathioprin, 6-mercaptopurin) – allopurinol ↑ their toxicity!
- **AE:** usually well tolerated, most common:

– rash, GIT intoleration, hypersensitive reaction

MUNI MED

Febuxostat

- **MA:** non-purine inhibitor of xantinoxidase
- clinical trials proved higher efficacy than allopurinol
- **AE:** gout attacts, liver function abnormalities, diarrhoea, nausea, headache

Pegloticase (recombinant uricase)

- **MA:** transforms uric acid to alantoin with better solubility
- **AE:** anaphylactic shock, reaction to infusion, gout attacts at the beginning of therapy
- i.v. aplication (only to inpatient)

MUNI MED